Accuray Incorporated (ARAY - Free Report) is gaining prominence in the MedTech space, courtesy of a strong international presence and solid demand for its flagship Radixact and CyberKnife platforms. However, a dull view for fiscal 2020 raises concern. The company also faces cutthroat competition in the radiation-oncology space.
Over the past year, shares of this Zacks Rank #3 (Hold) company have plunged 28.6% compared with the industry’s 4.1% decline. The current level also compares unfavorably with the S&P 500 index’s 2.3% rise.
What’s Favoring the Stock?
The Radixact and CyberKnife platforms continue to be major growth drivers for the company.
Radixact recently reported impressive fourth-quarter fiscal 2019 results. Radixact accounted for 60% of gross orders, while CyberKnife represented 40%.
Management is optimistic about Synchrony for Radixact and the VOLO upgrade on CyberKnife, which are expected to expand the company’s installed base.
Additionally, Accuray enjoys a strong overseas presence. For instance, the company received eight orders from China in the fiscal fourth quarter, which totaled $19 million. Management expects strong orders from China in fiscal 2020 as well.
Also, the company saw a rise in gross orders, courtesy of a strong show in the EMEA and APAC regions in the fiscal fourth quarter.
Accuray issued a dull guidance for fiscal 2020, courtesy of the tariffs in China.
Notably, the company expects revenues within $410-$420 million. Per management, Accuray has slashed its guidance by 1.5%. The company expects revenues from EMEA and Japan to remain flat or slightly below the fiscal 2019 levels. In the United States, Accuray expects modest revenue growth in fiscal 2020.
In fact, tariffs in China are also expected to negatively impact the fiscal 2020 gross margins by 150 basis points.
Apart from this, Accuray is exposed to stiff competition in the radiation oncology market from bigwigs like Varian Medical (VAR - Free Report) and Elekta AB among others.
Which Way Are Estimates Headed?
The Zacks Consensus Estimate for first-quarter fiscal 2020 bottom line is pegged at a loss of 10 cents. The same for revenues stands at $93.3 million.
For fiscal 2020, the Zacks Consensus Estimate for the bottom line is pinned at a loss of 14 cents, mirroring an improvement of 6.7%. The same for revenues is pegged at $417.7 million.
A few better-ranked stocks in the broader medical space are Stryker Corporation (SYK - Free Report) and Masimo Corporation (MASI - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker’s long-term earnings are expected to grow 10%.
Masimo’s long-term earnings are estimated to rise 20.5%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>